5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | NEUTRAL | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.60▼ | 1.58▲ | 1.59▼ | 1.39▲ | 1.19▲ |
MA10 | 1.59▲ | 1.62▼ | 1.60▼ | 1.16▲ | 0.97▲ |
MA20 | 1.58▲ | 1.63▼ | 1.51▲ | 1.05▲ | 1.16▲ |
MA50 | 1.63▼ | 1.45▲ | 1.28▲ | 0.89▲ | 5.84▼ |
MA100 | 1.64▼ | 1.25▲ | 1.13▲ | 1.28▲ | 12.28▼ |
MA200 | 1.50▲ | 1.11▲ | 0.95▲ | 4.08▼ | 22.67▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.006▲ | -0.023▼ | -0.011▼ | 0.069▲ | 0.439▲ |
RSI | 48.008▼ | 51.916▲ | 57.617▲ | 69.732▲ | 39.263▼ |
STOCH | 72.619 | 13.048▼ | 47.782 | 74.352 | 31.591 |
WILL %R | -44.444 | -78.462▼ | -51.515 | -23.437▲ | -45.665 |
CCI | 49.383 | -51.058 | -20.585 | 183.006▲ | 167.803▲ |
Tuesday, June 17, 2025 05:08 AM
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the ...
|
Friday, June 13, 2025 05:00 PM
Find the latest SEC Filings data for Citius Pharmaceuticals, Inc. Common Stock (CTXR) including 10-K and 10-Q forms at Nasdaq.com.
|
Thursday, June 12, 2025 01:35 AM
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/06/25 | 1.71 | 1.845 | 1.56 | 1.59 | 2,634,150 |
27/06/25 | 1.34 | 1.79 | 1.3198 | 1.53 | 5,542,195 |
26/06/25 | 1.23 | 1.34 | 1.18 | 1.33 | 863,194 |
25/06/25 | 1.26 | 1.45 | 1.16 | 1.20 | 2,861,377 |
24/06/25 | 1.05 | 1.33 | 0.99 | 1.29 | 5,823,392 |
23/06/25 | 1.16 | 1.25 | 0.969 | 1.03 | 1,646,723 |
20/06/25 | 0.938 | 1.24 | 0.8822 | 1.08 | 2,914,854 |
18/06/25 | 0.8449 | 0.98 | 0.8337 | 0.9126 | 661,235 |
17/06/25 | 0.80 | 0.8549 | 0.77 | 0.8533 | 574,157 |
16/06/25 | 0.83 | 0.85 | 0.757 | 0.7901 | 549,979 |
|
|
||||
|
|
||||
|
|